Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIVOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how SARS-CoV-2 infection reshapes the gut microbiota in people living with HIV, and whether those changes track with COVID-19 severity. Researchers analyzed stool over time using 16S rRNA gene sequencing. Samples from infected patients were grouped by time since onset: within 8 days, 8 to 14 days, and one month or later. They compared diversity and composition against uninfected controls and used LEfSe and predicted metabolic function to identify shifts and their links to disease course.
Who was studied?
The infected group was 12 hospitalized men living with HIV and confirmed COVID-19, with a median pre-infection CD4 count of 671 cells per microliter. Their median age was 47 years. Controls were 19 healthy adults and 25 uninfected people living with HIV, recruited in Tokyo, Japan. All patients had received antiretroviral therapy for over a year with suppressed HIV. Seven were mildly ill, four moderately, and one severely. Eight of the 12 had comorbidities such as asthma, diabetes, or dyslipidemia. All recovered and were discharged.
What were the most important findings?
Overall diversity in infected patients did not differ significantly from controls, but diversity did separate by disease severity. Mild cases showed a greater rise in diversity in the second week than moderate to severe cases. After onset, the Clostridia class fell, including short-chain fatty acid producers, while Gammaproteobacteria and Negativicutes rose. This dysbiosis persisted at least one month, sometimes after recovery. By one month, Enterobacteriaceae, mainly Escherichia-Shigella, increased and were enriched in the two patients who developed post-acute sequelae. Predicted carbohydrate, amino acid, and xenobiotic metabolism pathways were enhanced in infected patients.
What are the greatest implications of this study?
The findings suggest people living with HIV may show delayed recovery of the gut environment after COVID-19, even once the illness resolves. A persistent drop in short-chain fatty acid producers plus a rise in opportunistic pathogens could favor inflammation. The authors link this dysbiosis to COVID-19 severity and to post-acute sequelae, framing the gut as a potential contributor. The cohort was small, only 12 patients with just two developing long COVID, and lacked pre-infection samples. Conclusions are associative and need larger validation.